Sovremennye podkhody k terapii bol'nykh tsirrozom pecheni
- Authors: Yakovenko E.P1, Yakovenko A.V1, Kagramanova A.V1, Pryanishnikova A.S1, Ivanov A.N1, Agafonova N.A1, Volosheynikova T.V1, Grigor'eva Y.V1
-
Affiliations:
- Issue: No 13 (2012)
- Pages: 88-93
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279754
- ID: 279754
Cite item
Abstract
Full Text
About the authors
E. P Yakovenko
A. V Yakovenko
A. V Kagramanova
A. S Pryanishnikova
A. N Ivanov
N. A Agafonova
T. V Volosheynikova
Yu. V Grigor'eva
References
- Kuntz E, Kuntz H-D. Hepatology, Textbook and Atlas. Verlag: Springer Medizin Verlag Heidelberg. 2008:923.
- Sugimura Т, Tsuji Y, Sakamoto M, Kotoh K. Long term prognosis and prognostic factors of liver cirrhosis in the 1980s. J Gastroenterol Hepatol 1994;9:154-61.
- Шерлок Ш, Дули Д. Заболевания печени и желчных путей. Практическое руководство: Пер. с англ. / Под редакцией З.Г. Апросиной, И.А. Мухина. М., 1999. 964 с.
- Яковенко Э.П., Агафонова Н. А, Яковенко А.В. и др. Синдром избыточного бактериального роста в кишечнике - клиническое значение и вопросы терапии // Consilium medicum 2006. Экстравыпуск. С. 3-8.
- Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Bacterial flora in digestive disease. Focus on rifaximin Eds. Scarpignato С, Lanas A. Basel: Karger, 2006:15-39.
- Williams R, Rizzello F, Venturi A, et al. Antibiotic of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multicentre study. Eur J Gastroenterol Hepatol 2000;12:203-08.
- Zakim D, Boyer TD. Hepatology. A textbook of liver disease. 4th ed. Saunders Science (USA), 2003:1765.
- Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis В virus. Gastroenterology 1995;109:908-16.
- Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93.
- Weinstein WM, Hawkey CJ, Bosch J. Clinical Gastroenterology and Hepatology. Elsevie, 2005:1128.
- Lieber CS, Leo MA, Cao Q, et al. Silymarin retards the progression of alcohol - induced hepatitis fibrosis in baboons. J Clin Gastroenterol 2003;37:336-39.
- Ma X, Zhao J, Lieber CS. Polyenylpho-sphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatol 1996;24:604-13.
- Яковенко Э. П., Яковенко А. В., Иванов А.Н. и др. Лекарственно-индуцированные поражения печени. Диагностика и лечение // Лечащий врач 2011. № 2. С. 16-20.
- Bissel DM, Maher JJ. Hepatic fibrosis and cirrhosis. In: Zakim D, Boyer TD. (eds) Hepatology. A textbook of liver disease. 4th ed. Saunders Science (USA), 2003:395-416.
- Mathurin P, Carithers RL, Phillips M, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011;60:255-60.
- Григорьев П.Я., Яковенко А.В. Клиническая гастроэнтерология М., 2004. 748 с.
- Kamata Y, Nara H, Sato H, et al. Effect of steroid pulse therapy on mixed connective tisse disease with pulmonary arterial hypertension. Ann Rheum DIs 2005;64:1236-37.
- Wong F. Management of ascites in cirrhosis. J Gastroenterol Hepatol 2012;27:11-20.
- Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. Hepatology 1999;30:639-45.
- Tandon P, Tsuyuki RT, Mitchell L, et al. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int 2009;29:169-74.